192 related articles for article (PubMed ID: 38654153)
21. Eyes on New Product Development.
Novack GD
J Ocul Pharmacol Ther; 2017; 33(1):1-2. PubMed ID: 28080222
[No Abstract] [Full Text] [Related]
22. Dendrimers as a promising tool in ocular therapeutics: Latest advances and perspectives.
Rodríguez Villanueva J; Navarro MG; Rodríguez Villanueva L
Int J Pharm; 2016 Sep; 511(1):359-366. PubMed ID: 27436708
[TBL] [Abstract][Full Text] [Related]
23. Eyes on New Product Development.
Novack GD
J Ocul Pharmacol Ther; 2017 Apr; 33(3):129-131. PubMed ID: 28384030
[No Abstract] [Full Text] [Related]
24. Ocular drugs and drug delivery systems - Current trends and future perspectives.
Rupenthal ID; Daugherty AL
Drug Discov Today; 2019 Aug; 24(8):1425-1426. PubMed ID: 31330186
[No Abstract] [Full Text] [Related]
25. Nanotechnology in ocular drug delivery.
Sahoo SK; Dilnawaz F; Krishnakumar S
Drug Discov Today; 2008 Feb; 13(3-4):144-51. PubMed ID: 18275912
[TBL] [Abstract][Full Text] [Related]
26. Micelles: Promising Ocular Drug Carriers for Anterior and Posterior Segment Diseases.
Durgun ME; Güngör S; Özsoy Y
J Ocul Pharmacol Ther; 2020; 36(6):323-341. PubMed ID: 32310723
[TBL] [Abstract][Full Text] [Related]
27. Eyes on new product development.
Novack GD
J Ocul Pharmacol Ther; 2012 Dec; 28(6):557-8. PubMed ID: 23167518
[No Abstract] [Full Text] [Related]
28. Drug delivery to the posterior segment of the eye.
Fischer N; Narayanan R; Loewenstein A; Kuppermann BD
Eur J Ophthalmol; 2011; 21 Suppl 6():S20-6. PubMed ID: 23264325
[TBL] [Abstract][Full Text] [Related]
29. Preface.
Vavvas D; Gragoudas ES; Hatton MP
Int Ophthalmol Clin; 2004; 44(3):xiii. PubMed ID: 15211188
[No Abstract] [Full Text] [Related]
30. Considerations for randomizing 1 eye or 2 eyes.
Bunce C; Wormald R
JAMA Ophthalmol; 2015 Oct; 133(10):1221. PubMed ID: 26291489
[No Abstract] [Full Text] [Related]
31. In Vivo Studies Evaluating the Use of Contact Lenses for Drug Delivery.
Hui A; Willcox M
Optom Vis Sci; 2016 Apr; 93(4):367-76. PubMed ID: 26784709
[TBL] [Abstract][Full Text] [Related]
32. Nanocarriers for treatment of ocular neovascularization in the back of the eye: new vehicles for ophthalmic drug delivery.
Shen HH; Chan EC; Lee JH; Bee YS; Lin TW; Dusting GJ; Liu GS
Nanomedicine (Lond); 2015; 10(13):2093-107. PubMed ID: 26096379
[TBL] [Abstract][Full Text] [Related]
33. Considerations for randomizing 1 eye or 2 eyes--reply.
Glassman AR; Melia M
JAMA Ophthalmol; 2015 Oct; 133(10):1221. PubMed ID: 26291566
[No Abstract] [Full Text] [Related]
34. A New Direction in Ophthalmic Development: Nanoparticle Drug Delivery Systems.
Andonova VY
Curr Pharm Des; 2016; 22(41):6313-6329. PubMed ID: 27526789
[TBL] [Abstract][Full Text] [Related]
35. Potential use of ocular-insert therapy in dry eyes.
Pavan-Langston D
Int Ophthalmol Clin; 1973; 13(1):231-8. PubMed ID: 4724259
[No Abstract] [Full Text] [Related]
36. Ocular Therapeutics: Drug Delivery and Pharmacology.
Dickmann L
Mol Pharm; 2016 Sep; 13(9):2875-6. PubMed ID: 27596048
[No Abstract] [Full Text] [Related]
37. Randomizing 1 eye or 2 eyes: a missed opportunity.
Glassman AR; Melia M
JAMA Ophthalmol; 2015 Jan; 133(1):9-10. PubMed ID: 25256889
[No Abstract] [Full Text] [Related]
38. Applications of microneedles in delivering drugs for various ocular diseases.
Gupta P; Yadav KS
Life Sci; 2019 Nov; 237():116907. PubMed ID: 31606378
[TBL] [Abstract][Full Text] [Related]
39. A review on recent drug delivery systems for posterior segment of eye.
Nayak K; Misra M
Biomed Pharmacother; 2018 Nov; 107():1564-1582. PubMed ID: 30257375
[TBL] [Abstract][Full Text] [Related]
40. Current and future ophthalmic drug delivery systems. A shift to the posterior segment.
Del Amo EM; Urtti A
Drug Discov Today; 2008 Feb; 13(3-4):135-43. PubMed ID: 18275911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
